Entera Bio (ENTX)
(Delayed Data from NSDQ)
$2.10 USD
-0.06 (-2.78%)
Updated Dec 20, 2024 04:00 PM ET
After-Market: $2.09 -0.01 (-0.48%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth C Momentum F VGM
Price, Consensus and EPS Surprise
ENTX 2.10 -0.06(-2.78%)
Will ENTX be a Portfolio Killer in December?
Zacks Investment Research is releasing its prediction for ENTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ENTX
Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates
Are Medical Stocks Lagging Argenx (ARGX) This Year?
ENTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data
Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year?
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
Other News for ENTX
Knoll Capital Management, LLC's Strategic Acquisition in Entera Bio Ltd
Entera Bio Buy Rating: Strong Financials, Strategic Developments, and Promising Pipeline Drive Analyst Confidence
Entera Bio GAAP EPS of -$0.08 misses by $0.03, revenue of $0.04M in-line
Entera Bio Highlights Q3 2024 Financials and FDA Anticipation
Buy Rating Affirmed for Entera Bio’s EB613: A Game Changer in Osteoporosis Treatment